Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets

Market Research Report | 2023-10-13 | 131 pages | BCC Research

AVAILABLE LICENSES:

- Single User License $5500.00
- 2-5 Users License $6600.00
- Site License $7920.00
- Enterprise License $9504.00

Report description:

Description

Report Scope:

The scope of the report includes biologics CDMO services, industries, initiatives, patents, and companies. The markets for biologics CDMO are given for 2020, 2021, 2022, 2023 and 2028.

This report explains why biologics CDMO is important in pharmaceutical and biotechnology industry. It then discusses some of the significant research initiatives that are impacting biologics CDMO. The main market-driving forces are also discussed.

The report examines the markets by product type, cell line type and region. The report provides market data and forecasts for biologics CDMO by product type, including biologics and biosimilars. The specific regional markets covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW).

In the report BCC Research summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022.

Report Includes:

- 40 data tables and 10 additional tables
- An up-to-date overview and industry analysis of the global markets for biologics contract development and manufacturing

organizations (CDMO)
- Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Estimation of the actual market size and revenue forecast for biologics CDMO market in USD million values, and their corresponding market share analysis based on the product type, cell line type, and geographic region
- In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of macroeconomic variables on biologics CDMO marketplace
- Discussion of ESG developments in global CDMO services market, with emphasis on importance of ESG, consumer attitudes, risks and opportunity assessment, and ESG followed practices
- Identification of the pharma companies that are considered as leaders in their field, as well as technological means these companies are using to exploit their markets and dominate the market in their fields
- Market outlook and opportunity assessment of the industry structure for biologics CDMO services, and evaluation of ongoing clinical trials and R&D activities estimating current and future market demand
- Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
- Analysis of the company competitive landscape based on recent developments, key financials, and operational integration
- Company profiles of major players within the industry, including Lonza Group, WuXi Biologics, Samsung Biologics, Boehringer Ingelheim, and Catalent Inc.

Executive Summary

Summary:

Contract development and manufacturing organizations serve the pharmaceutical industry and provide clients with services such as drug development, process development, analytical testing, formulation development, scale-up, manufacturing, packaging and distribution. These services can be provided on a standalone basis or as part of an end-to-end service offering.

A biologics contract development and manufacturing organization (CDMO) provides pharmaceutical companies with biological medical product development and manufacturing services. This type of CDMO may either specialize in developing and manufacturing biologics alone, or may offer these same services for biologics and small molecule drugs. Biologics is a general term for drugs manufactured using biotechnology. Unlike small-molecule drugs chemically manufactured, biologics are complex molecules, such as proteins or cells used as medicinal ingredients.

When a pharmaceutical company discovers a new medical biologic, it may choose to partner with a biologics CDMO to outsource one or more steps of the development and manufacturing process. Some biologics CDMOs focus on supporting certain parts of the development process, while full-service biologics CDMOs have the capability to handle each stage of drug development and manufacturing. Biologics CDMOs are valuable resources for pharmaceutical companies, as they have extensive experience navigating everything from pre-formulation to clinical trials and commercial production.

The global biologics CDMO market was valued at nearly $REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to reach $REDACTED billion by the end of 2028. Growth in this market is fueled by the increasing R&D activities, prevalence of chronic diseases, rising demand for biologics, increasing aging populations, continuing investment in healthcare infrastructure, and the perpetual parade of new products.
In this report, the global market for biologics CDMO is segmented into product type, cell line type and geographic region. Product types include biologics and biosimilars.

Biologics CDMO companies are concentrating on pharmaceutical and biotechnology companies to provide services for drug

development. For instance, in April 2022, ChimeronBio signed a manufacturing agreement with FujiFilm Diosynth Biotechnologies (FDB) to expand its oncology portfolio to include clinics. ChimeronBio selected FDB as its partner for transferring and scaling its drug substance manufacturing process.

The global market for biologics CDMO by cell line type is categorized into mammalian, microbial and other modalities. The mammalian segment is expected to increase from $REDACTED billion in 2022 to $REDACTED billion by the end of 2028, at a CAGR of REDACTED% for the period.

Table of Contents:

Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets

Market Research Report | 2023-10-13 | 131 pages | BCC Research

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$5500.00
	2-5 Users License	$6600.00
	Site License	$7920.00
	Enterprise License	$9504.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-03-03
		Signature